Resting Platelet Signaling Before Any Antiplatelet Drug
A short placeholder overview of normal platelet activation biology.
- 100%: COX-1 activity (placeholder baseline value)
- 100%: P2Y12 activity (placeholder baseline value)
- High: TXA2 output (placeholder synthesis level)
- Full: Aggregation (placeholder response level)
How platelets normally activate and aggregate
Placeholder short description of collagen/ADP/thromboxane activation loop.
Aspirin Irreversibly Acetylates the COX-1 Active Site
A short placeholder overview of aspirin acetylating serine-530 on COX-1.
- Irreversible: Acetylation (placeholder mechanism note)
- ~30 min: Onset (placeholder timing value)
- Platelet lifespan: Duration (placeholder ~10 days)
- 75-100mg: Dose typical (placeholder daily dose)
Mechanism of COX-1 acetylation by aspirin
Placeholder short description of serine acetylation blocking arachidonic acid access.
Loss of Thromboxane A2 Weakens Platelet Recruitment
A short placeholder overview of downstream TXA2 pathway suppression.
- Suppressed: TXA2 synthesis (placeholder outcome)
- Reduced: TXA2 receptor signal (placeholder outcome)
- Reduced: Vasoconstriction (placeholder outcome)
- Weakened: Recruitment (placeholder outcome)
Downstream effect of losing thromboxane A2
Placeholder short description linking COX-1 blockade to reduced amplification.
Clopidogrel and Ticagrelor Block the ADP Receptor
A short placeholder overview of P2Y12 receptor antagonism.
- Irreversible: Clopidogrel type (placeholder prodrug note)
- Reversible: Ticagrelor type (placeholder direct-acting note)
- P2Y12 receptor: Target (placeholder ADP receptor)
- Blocks amplification: Effect (placeholder outcome)
Mechanism of P2Y12 receptor antagonism
Placeholder short description of ADP-driven activation loop being interrupted.
Combining Both Pathways for Stronger Platelet Suppression
A short placeholder overview of combined dual antiplatelet therapy benefit.
- High: Combined suppression (placeholder synergy note)
- Lowered: Stent thrombosis risk (placeholder clinical benefit)
- Increased: Bleeding risk (placeholder tradeoff note)
- Post-PCI: Typical use (placeholder clinical context)
Why dual antiplatelet therapy is used together
Placeholder short description of synergistic dual-pathway platelet inhibition.
Placeholder key takeaway about DAPT balancing thrombosis and bleeding risk.